NCT03534284View on ClinicalTrials.gov

Short and Long-Term Effectiveness of Existing Insomnia Therapies for Patients Undergoing Hemodialysis

PHASE3CompletedINTERVENTIONAL
Enrollment

126

Participants

Timeline

Start Date

September 19, 2018

Primary Completion Date

October 17, 2022

Study Completion Date

November 17, 2022

Conditions
InsomniaEnd Stage Renal Disease
Interventions
BEHAVIORAL

Cognitive Behavioral Therapy for Insomnia

Once weekly treatment sessions for 6 weeks. The content of each of these sessions will be adapted to include changes in behavior during HD treatments (such as napping) and to help patients better adjust to treatment schedules. The CBT-I sessions will be delivered by a therapist face-to-face with the patient via a fully interactive video telehealth platform.

DRUG

Trazodone

trazodone tablet

DRUG

Placebo

Inactive pill manufactured to mimic trazodone tablets.

Trial Locations (1)

98122

Northwest Kidney Centers, Seattle

All Listed Sponsors
collaborator

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

NIH

lead

University of Washington

OTHER

NCT03534284 - Short and Long-Term Effectiveness of Existing Insomnia Therapies for Patients Undergoing Hemodialysis | Biotech Hunter | Biotech Hunter